Fixed combination of perindopril and indapamide at low dose improves endothelial function in essential hypertensive patients after acute administration

American Journal of Hypertension

Volumn 21, Issue 6, 2008, Pages 679-684

  Joannides, Robinson ^a   Bellien, Jeremy ^a   Thurlure, Celine ^a   Iacob, Michele ^a   Abeel, Murielle ^b   Thuillez, Christian ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; INDAPAMIDE; PERINDOPRIL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; HYPEREMIA; HYPERTENSION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD CIRCULATION; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; NITROGLYCERIN; PERINDOPRIL; RADIAL ARTERY;

EID: 44349163642     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.39     Document Type: Article

References (36)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
3. Hermann M, Flammer A, Luscher TF. Nitric oxide in hypertension. J Clin Hypertens 2006; 8:17-29.
4. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20:1671-1674.
5. Joannidès R, Richard V, Thuillez C. Pulsatile stress, arterial stiffness, endothelial function. In Safar ME, O'Rourke ME (eds), Handbook of Hypertension, Arterial Stiffness in Hypertension. Elsevier: Edinburgh, London, New York, Oxford, Philadelphia, Saint Louis, Sydney, Toronto, 2006, pp 99-124.
6. Muiesan ML, Salvetti M, Paini A, Monteduro C, Poisa P, Galbassini G, Stanga B, Paderno V, Porteri E, Rizzoni D, Agabiti Rosei E. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2006; 24:S299. (abstract).
7. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40:505-510.
8. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41:1281-1286.
9. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin Pharmacokinet 1999; 37:7-12.
10. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J, Mikami H, Ogihara T. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132:779-782.
11. Lauer T, Heiss C, Preik M, Balzer J, Hafner D, Strauer BE, Kelm M. Reduction of peripheral flow reserve impairs endothelial function in conduit arteries of patients with essential hypertension. J Hypertens 2005; 23:563-569.
12. Joannides R, Bakkali EIH, Richard V, Moore N, Thuillez C. Evaluation of the determinants of flow-mediated radial artery vasodilatation in humans. Clin Exper Hypertens 1997; 12:813-826.
13. Joannides R, Haefeli W, Linder L, Richard V, Bakkali EIH, Thuillez C, Lüscher T. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
14. Bellien J, Iacob M, Gutierrez L, Isabelle M, Lahary A, Thuillez C, Joannides R. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension 2006; 48:1088-1094.
15. Bellien J, Iacob M, Eltachaninoff H, Bourkaib R, Thuillez C, Joannides R. Angiotensin II type 1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NO-synthase inhibition. Clin Sci (Lond) 2007; 112:393-401.
16. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, Müller M, Busse R, Fleming I, Drexler H. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 2007; 9:770-775.
17. Pyke KE, Tschakovsky ME. Peak vs. total reactive hyperemia: which determines the magnitude of flow-mediated dilation? J Appl Physiol 2007; 102:1510-9.
18. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29:286-290.
19. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001; 37:863-870.
20. Ishibashi Y, Takahashi N, Shimada T, Sugamori T, Sakane T, Umeno T, Hirano Y, Oyake N, Murakami Y. Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. Circ J 2006; 70:115-123.
21. Conway J. A vascular abnormality in hypertension. A study of blood flow in the forearm. Circulation 1963; 27:520-529.
22. Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. Br J Clin Pharmacol 2001; 52:25-33.
23. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000; 14:139-146.
24. Valvo E, Gammaro L, Bedogna V, Tonon M, Giorgetti P, Pica B, Antonini P, Tessitore N, Oldrizzi L, Rugiu C et al. Systemic and renal hemodynamic changes after two-month treatment with enalapril in patients with essential hypertension. Int J Clin Pharmacol Ther Toxicol 1987; 25:656-659.
25. Chau NP, Simon A, Vilar J, Cabrera-Fischer E, Pithois-Merli I, Levenson J. Active and passive effects of antihypertensive drugs on large artery diameter and elasticity in human essential hypertension. J Cardiovasc Pharmacol 1992; 19:78-85.
26. Mourad JJ, Hanon O, Deverre JR, Camici PG, Sellier P, Duboc D, Safar ME. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003; 4:94-95.
27. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94:3115-3122.
28. Richard V, Joannides R, Henry JP, Mulder P, Mace B, Guez D, Schiavi P, Thuillez C. Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: haemodynamic, biological and structural effects. J Hypertens 1996; 14:1447-1454.
29. Luccioni R, Frances Y, Gass R, Schwab C, Santoni JP, Perret L. Evaluation of the dose-effect relationship of a new ace inhibitor (perindopril) by an automatic blood pressure recorder. Eur Heart J 1988; 9:1131-1136.
30. Villarreal H, Nuñez-Poissot E, Anguas MC, Degandarias L, Meza U. Effects of the acute and chronic administration of indapamide on systemic and renal haemodynamics in essential hypertension. Curr Med Res Opin 1983; 8:135-139.
31. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 2006; 24:S45-S50.
32. Vergely C, Walker MK, Zeller M, Rademakers JR, Maupoil V, Schiavi P, Guez D, Rochette L. Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance. Mol Cell Biochem 1998; 178:151-155.
33. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-1118.
34. Junquero DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-dependent production of cyclic guanosine monophosphate by bradykinin in the canine femoral artery. Am Heart J 1991; 122:1204-1209.
35. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993; 92:2867-2871.
36. Calder JA, Schachter M, Sever PS. Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine. Eur J Pharmacol 1994; 256:185-191.